Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER staff changes

This article was originally published in The Gray Sheet

Executive Summary

Sixty-three of 213 CBER Office of Therapeutic Research & Review FTEs are reassigned to CBER's Office of Cellular Tissue & Gene Therapies, while the remaining FTEs will be transferred to the drug center, FDA reports. The Jan. 8 agency memo details phase two of a three-part plan to shift review of biologic therapeutic products to the Center for Drug Evaluation & Research. The restructuring was announced last fall (1"The Gray Sheet" Nov. 22, 2002, p.11)...
Advertisement

Related Content

CBER Reorganization Poses “Significant” Staff Retention Issues – Zoon
CBER Reorganization Poses “Significant” Staff Retention Issues – Zoon
Advertisement
UsernamePublicRestriction

Register

MT017720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel